WeTrials
Recruiting

Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID)

What is this study?

This study is testing a targeted cancer medication called olaparib for people with kidney cancer that has spread to other parts of the body. It focuses on patients who have specific genetic changes in their DNA repair genes.

Who can participate?

You may be able to join if you are 18 or older, have advanced kidney cancer, and testing has shown you have specific gene changes like BAP-1. You must also have had at least one prior treatment for your kidney cancer.

What will happen?

Participants will take an oral medication called olaparib by mouth and have regular check-ups to see how well the treatment is working and monitor your health.

Where and when?

This study is currently recruiting participants and takes place in Baltimore, Maryland, United States.

Key Points
  • 1Tests the targeted medication olaparib for advanced kidney cancer.
  • 2Requires specific genetic mutations found through testing.
  • 3Currently actively recruiting patients in Baltimore, Maryland.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Renal Cell CarcinomaMetastatic Renal Cell CarcinomaKidney CancerRenal CarcinomaKidney Cancer Metastatic

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.